Euros for Discoveries?

Many US academic researchers patent discoveries even before they publish them, contributing to $1.26 billion (US) in new product licenses in 2001. Now some European institutions want to catch up, but century-old traditions slow their pace. "A lot of the research at universities and institutions is focused on publication and the scientists are not focused on patents and commercializing their research results," says Mattheas Konrad, biotechnology manager of Bayern-Innovativ, a technology transfer

Written byTed Agres
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Because Europe trails the United States by 10 to 15 years, universities and institutes forgo hundreds of millions of dollars in revenues from licensing and company startups that could pay for additional research and reward innovation. "In many places in Europe, technology transfer has been left to the individual scientist and academic with little participation by the university," says Martin Wood, director of licensing and agreements for Medical Research Council (MRC) Technology, the licensing arm of the MRC in London.

But European scientists and institutions are changing to keep up with their US counterparts and encourage talented scientists to remain in their own countries, according to top technology transfer experts.

Each European country has its own situation regarding ownership of intellectual property; they lack consensus, says Rudy Dekeyser, technology transfer manager and general director of the Flanders Interuniversity Institute for Biotechnology (VIB) in Belgium. VIB manages technology transfer for nine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies